Medicinal Cannabis in Workers' Compensation NSW
Assessing safety, appropriateness, and risk in SIRA-regulated claims
3 April 2026
Introduction
Medicinal cannabis prescribing in NSW workers' compensation claims has increased significantly since legalization in 2016. While some workers with chronic pain or spasticity may benefit from cannabis-based medicines, their use in SIRA-regulated claims requires careful assessment. As an insurer, you need to understand the evidence base, identify inappropriate use, and recognize where pharmacist-led medication reviews add critical value.
Unlike established pharmaceuticals, medicinal cannabis products vary widely in cannabinoid content, and long-term outcomes data remains limited. Your pharmacist review identifies whether your worker's cannabis therapy aligns with current clinical evidence and whether your claims costs are justified.
Medicinal Cannabis in NSW Workers' Compensation Context
NSW workers who have exhausted conventional pain management options may be referred for medicinal cannabis assessment. Common conditions include chronic pain from industrial injuries, neuropathic pain, and post-operative pain. However, the evidence base for medicinal cannabis is uneven:
- Strong evidence supports cannabis for neuropathic pain and cancer pain
- Moderate evidence supports use in chronic pain; results are variable and often modest
- Limited evidence supports cannabis for musculoskeletal pain alone
- Evidence for spasticity improvement is established, but outcomes vary
Regulatory Framework in NSW
Medicinal cannabis in NSW is regulated under the Therapeutic Goods Act 1989 and state-level approval processes. Your worker's cannabis prescription should come from an authorized prescriber and be dispensed through authorized pharmacies. Products must contain THC and/or CBD at specified potencies.
SIRA (State Insurance Regulatory Authority) does not prohibit medicinal cannabis in workers' compensation claims, but expects medical justification and regular review. Your pharmacist reviewer checks:
- Is the prescriber authorized to prescribe medicinal cannabis?
- Is the cannabis product TGA-approved or appropriately licensed?
- Is there documented medical rationale for cannabis use?
- Has conventional treatment been adequately trialed?
Why Medicinal Cannabis Requires Pharmacist Review
Unlike opioids or benzodiazepines, medicinal cannabis lacks established dosing guidelines and long-term safety data. Your pharmacist review performs functions that medical records alone cannot provide:
1. Cannabinoid Composition Assessment
Your pharmacist examines your worker's specific cannabis product. Is it a high-THC formulation, CBD-dominant, or balanced? THC-dominant products carry higher risks for cognitive impairment, dependence, and psychiatric symptoms. CBD-only formulations carry fewer risks but also less evidence of benefit.
2. Dose Appropriateness
Cannabis dosing varies widely. Your pharmacist assesses whether your worker's THC dose is proportionate to their condition and whether escalation patterns suggest tolerance or inadequate response. Escalating THC doses without documented functional improvement may indicate inappropriate use or cannabis use disorder risk.
3. Drug Interaction Screening
Cannabis interacts with multiple medications common in workers' compensation claims: opioids (additive CNS depression), benzodiazepines (increased sedation and fall risk), anticoagulants, and antidepressants. Your pharmacist flags these interactions and assesses whether dose adjustments or alternative agents are warranted.
4. Functional Outcomes Tracking
Is your worker demonstrating functional improvement on medicinal cannabis? Many workers show subjective symptom relief but lack objective gains in activities of daily living, work capacity, or pain-related disability. Your pharmacist review identifies workers where cannabis has plateaued or failed to deliver expected functional improvement.
5. Substitution Analysis
Has your worker reduced other medications (particularly opioids or benzodiazepines) since starting medicinal cannabis? In ideal cases, cannabis therapy allows dose reduction or cessation of higher-risk medications. If cannabis is simply added without reducing other medications, your claims burden increases without proportional benefit.
Cannabis and Concurrent Opioid Use
A common and concerning scenario in workers' compensation claims is concurrent medicinal cannabis and opioid use. This combination carries significant risks:
| Risk Factor | Clinical Concern |
|---|---|
| Respiratory depression | Both opioids and THC depress respiratory drive; concurrent use increases overdose risk |
| Cognitive impairment | Additive CNS effects worsen driving safety and return-to-work capacity |
| Fall risk | Both medications impair balance and proprioception, increasing falls in elderly or impaired workers |
| Medication diversion | Concurrent controlled substances increase abuse potential and insurance fraud risk |
If your worker is on both opioids and medicinal cannabis, your pharmacist review should establish whether a dose-reduction strategy for one or both medications is appropriate.
Red Flags in Workers' Cannabis Use
Escalate your worker's case for pharmacist review if any of these patterns emerge:
- Cannabis dose escalating monthly without corresponding functional improvement
- Concurrent opioid and benzodiazepine use alongside cannabis
- Long-term cannabis use (beyond 12 months) without documented off-ramp strategy
- Cannabis initiated by prescriber unfamiliar with cannabis safety in workers' compensation
- Persistent cognitive complaints or driving safety concerns since cannabis initiation
- No reduction in other pain medications despite cannabis addition
- Worker reporting loss of productive activity or worsening work capacity since cannabis start
Evidence-Based Use Cases
Medicinal cannabis has strongest evidence and most defensible role in specific worker scenarios:
Neuropathic Pain (Post-Trauma or Surgical Nerve Damage)
Workers with documented neuropathic pain (e.g., post-motor accident nerve injury, complex regional pain syndrome) represent the strongest evidence base for cannabis. If conventional neuropathic agents (gabapentin, pregabalin, duloxetine) have failed or caused intolerable side effects, cannabis may offer genuine benefit.
Spasticity (Post-Traumatic or Post-Surgical)
Cannabis has established benefit for reducing muscle spasticity. Workers with documented spasticity from spinal cord injury or traumatic brain injury who have failed conventional muscle relaxants represent an appropriate use case.
Cancer Pain (Occupational Disease Claims)
Workers with cancer diagnoses arising from occupational exposure (e.g., mesothelioma, occupational lung cancer) may benefit from cannabis alongside conventional cancer pain management.
Chronic Pain After Failed Conventional Therapy
Workers with chronic pain from industrial injury who have genuinely exhausted conventional options (opioids, non-opioids, injections, surgery, physiotherapy, pain psychology) may be candidates if functional improvement potential exists.
The Pharmacist's Role in Cannabis Assessment
Your pharmacy medication review examines your worker's entire therapeutic context and answers critical questions:
- Is the indication appropriate? Does your worker's condition align with evidence-based cannabis use cases?
- Was conventional therapy adequately trialed? Are the documented trials genuine, or were higher doses or longer durations of conventional agents needed?
- Is the cannabis product appropriate? Does the THC:CBD ratio and absolute dose match the indication?
- Are interactions managed? Are concurrent medications adjusted for cannabis interaction risk?
- Is functional improvement occurring? Can your worker demonstrate objective gains (reduced pain scores, improved mobility, increased work capacity) since cannabis initiation?
- Is the cost justified? Medicinal cannabis often costs significantly more than conventional alternatives; does your worker's response justify the cost premium?
Conclusion
Medicinal cannabis has legitimate therapeutic roles in NSW workers' compensation claims, particularly for neuropathic pain, spasticity, and chronic pain after failed conventional therapy. However, not all workers benefit, and inappropriate use can increase your claims costs without proportional functional improvement.
Your pharmacist-led medication review assesses whether your worker's cannabis therapy aligns with clinical evidence, whether conventional alternatives were adequately trialed, and whether functional outcomes justify continued use. This review protects your claims economics while ensuring your workers access appropriate, evidence-based medication management.
Is your NSW worker using medicinal cannabis?
A pharmacist medication review can assess whether your worker's cannabis therapy is evidence-based, appropriately dosed, and delivering functional improvement. We'll identify any interaction risks with concurrent medications and recommend whether your worker should continue, adjust, or transition away from medicinal cannabis.
Request a Medication Review
